Live Breaking News & Updates on Aeterna zentaris gmb

Stay informed with the latest breaking news from Aeterna zentaris gmb on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Aeterna zentaris gmb and stay connected to the pulse of your community

Aeterna Zentaris : THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOUR OF ALL PROPOSED RESOLUTIONS - Form 6-K

THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOUR OF ALL PROPOSED RESOLUTIONS.

YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY.

May 9, 2023

... | May 23, 2023

Michigan , United-states , Brussels , Bruxelles-capitale , Belgium , Quebec , Canada , District-of-columbia , Seattle , Washington , Russia , Illinois

Aeterna Zentaris Announces the Selection of a Development

–
In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study.

AEZS-150 has the potential to become a new therapeutic treatment option of primary hypoparathyroidism.
CHARLESTON, S.C., May 06, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that, in consultation with The University of Sheffield, UK (the “University”), Aeterna has selected AEZS-150 as the lead candidate in the Company’s delayed clearance parathyroid hormone fusion polypeptides (DC-PTH) program. Aeterna will now start the formal preclinical development of AEZS-150 in preparation for a potential IND filing for conducting the first in-human clinical study of AEZS-150. AEZS-150 is being developed with the goal of providing a potential new treatment option of primary hypoparathyroidism in adults.

Canada , United-kingdom , Canadian , Jenene-thomas , Aeterna-zentaris-gmb , Richardj-ross , Klaus-paulini , United-kingdom-the-university , Linkedin , Aeterna-zentaris , Company-on-twitter , European-commission

Aeterna Zentaris Announces Exclusive License Agreement and

- Company secures next step to continue to build-out pipeline of assets - Company exercised its option to enter into an exclusive license of...

China , Germany , United-states , United-kingdom , Israel , Hubei , Guangdong , Wuhan , Canada , Palestinian , Canadian , Jenene-thomas

Aeterna Zentaris Announces the Selection of a Development

–
In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study.

AEZS-150 has the potential to become a new therapeutic treatment option of primary hypoparathyroidism.
CHARLESTON, S.C., May 06, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that, in consultation with The University of Sheffield, UK (the “University”), Aeterna has selected AEZS-150 as the lead candidate in the Company’s delayed clearance parathyroid hormone fusion polypeptides (DC-PTH) program. Aeterna will now start the formal preclinical development of AEZS-150 in preparation for a potential IND filing for conducting the first in-human clinical study of AEZS-150. AEZS-150 is being developed with the goal of providing a potential new treatment option of primary hypoparathyroidism in adults.

United-kingdom , Richardj-ross , Aeterna-zentaris-gmb , Klaus-paulini , United-kingdom-the-university , Linkedin , Aeterna-zentaris , Company-on-twitter , European-commission , Nasdaq , University-of-sheffield , Aeterna-zentaris-inc

Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Canada , United-kingdom , Canadian , Jenene-thomas , Aeterna-zentaris-gmb , Richardj-ross , Klaus-paulini , United-kingdom-the-university , Linkedin , Aeterna-zentaris , Company-on-twitter , European-commission

DGAP-News: Atriva Therapeutics GmbH: Atriva Therapeutics Announces Changes to Management

DGAP-News: Atriva Therapeutics GmbH: Atriva Therapeutics Announces Changes to Management
Atriva Therapeutics Announces Changes to Management
13.04.2021 / 09:30
Atriva Therapeutics Announces Changes to Management
- Olaf Althaus appointed Chief Financial Officer
- Stephan Stenglein, M.D., recently joined as Chief Medical Officer
- Proven track record and 20+ years of experience in their respective fields of expertise
Tübingen (Germany), April 13, 2021 - Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, today announced two changes to its management team. Olaf Althaus was appointed Chief Financial Officer, effective May 2020, while Stephan Stenglein, M.D., was named Chief Medical Officer, effective February 2021.

Frankfurt-am-main , Hessen , Germany , Haasbach , Nordrhein-westfalen , London , City-of , United-kingdom , Eva-bauer-raimund-gabriel , Olaf-althaus , Stephan-stenglein , Kostenloser-wertpapierhandel

Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism

Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism
March 11, 2021 08:05 ET
| Source:
Aeterna Zentaris Inc
Aeterna Zentaris Inc
Montreal CANADA
– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will initially be studied by Aeterna for the potential therapeutic treatment of primary hypoparathyroidism
–
Continued execution on growth strategy to establish a diversified, yet focused, pipeline of development assets leveraging the Company’s expertise and experience
CHARLESTON, S.C., March 11, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it is continuing to expand its development pipeline by initiating a preclinical development program to develop parathyroid hormone fusion polypeptides (PTH) with delayed clearance based on proprietary intellectual property exclusively licensed by Aeterna from The University of Sheffield, UK (the “University”).

United-states , United-kingdom , Israel , Palestinian , Aeterna-zentaris-gmb , Richardj-ross , Klaus-paulini , Boeing , Aeterna-zentaris , Megapharm-ltd , Nasdaq , Aeterna-zentaris-inc

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

China , Germany , United-states , United-kingdom , Israel , Hubei , Guangdong , Wuhan , Canada , Palestinian , Canadian , Jenene-thomas

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with ...

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with ...
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

China , Germany , United-states , United-kingdom , Israel , Hubei , Guangdong , Wuhan , Canada , Palestinian , Canadian , Jenene-thomas

Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism

– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides…

United-states , Canada , United-kingdom , Israel , Palestinian , Canadian , Jenene-thomas , Aeterna-zentaris-gmb , Richardj-ross , Klaus-paulini , Boeing , Aeterna-zentaris